Adam Friedman, MD: Addressing Disparities in Care for Patients with Atopic Dermatitis

Video

In this interview, Friedman described his conference presentation on treating atopic dermatitis through telemedicine to address the disparities in care that are visible around the world.

During this HCPLive interview, Adam Friedman, MD, spoke on concerns about disparities between different groups with atopic dermatitis and the ways in which he hopes to address them.

Friedman’s discussion was the result of his presentation from the Revolutionizing Atopic Dermatitis (RAD) 2023 Annual Meeting in Washington, DC., during which he presented on “Using teledermatology to reduce disparities in atopic dermatitis care.”

He is known for his work as Professor and Chair of Dermatology in the Department of Dermatology at the George Washington University School of Medicine & Health Sciences.

“I think there's certainly more global disparities,” he explained. “And there are a lot of different reasons for them. I think that they range from when we say access, that can mean a lot of things. It can mean having a physician or a specialist in your area that you can physically access or even if you do, can you even get into see that person because they're so overwhelmed with patients, does it mean that you can physically get there, (or) whether you have the means to get to a visit?”

He added that there are disparities between different populations, noting that there are many different subgroups and variables.

“But we do see with atopic dermatitis, for example, those who identify as black depending on certain studies or African American—often those terms are put side by side and they're not the same, but that's what we see—that there is a higher prevalence of disease, more severe disease,” he said. “But those individuals make up a very small subset of those who are actually being seen by dermatologists.

Friedman added that dermatologists know that socioeconomic status is an independent risk factor for more severe and uncontrolled diseases.

“So I think there's a lot more to learn and I think the way we solicit information will ultimately lend itself to better understanding the needs of specific communities and populations,” he explained. “But certainly from the information we have, there are those who seem to be at higher risk for all the horrific primary and secondary things that atopic dermatitis can cause and lead to down the road.”

For more information about Friedman’s presentation, view the full interview segment above.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.